SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)
$CRDF
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2026 | $2.00 | Buy → Hold | Craig Hallum |
| 6/1/2026 | Buy → Neutral | H.C. Wainwright | |
| 6/1/2026 | Buy → Hold | TD Cowen | |
| 1/5/2026 | $12.00 | Outperform | Noble Capital Markets |
| 7/8/2025 | $19.00 | Buy | Ladenburg Thalmann |
| 6/24/2025 | $3.50 | Hold | Jefferies |
| 9/6/2024 | $8.00 | Buy | Craig Hallum |
| 2/28/2022 | $26.00 → $25.00 | Buy | HC Wainwright & Co. |
Craig Hallum downgraded Cardiff Oncology from Buy to Hold and set a new price target of $2.00
H.C. Wainwright downgraded Cardiff Oncology from Buy to Neutral
TD Cowen downgraded Cardiff Oncology from Buy to Hold
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC - - Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, with nine of the 14 patients remaining on treatment in these arms - - Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities when added to SoC - - Registrational trial planned in first-line RAS-mutated mCRC following successful End-of-Phase
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026. Details of the presentation can be found below. Format: Fireside ChatPresenter: Mani Mohindru, PhD (President and CEO) Date: 06/04/2026 Time: 10:30 -11:00 AM ET Interested parties can register for and access the live webcast for the conference by visiting the "Events" section of the Cardiff Oncology website. The webcast repl
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it will host an investor webcast featuring members of management on June 3, 2026 at 8:30 am ET to review updated data from CRDF-004, a randomized dose-finding Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care regimens (FOLFIRI/bevacizumab or FOLFOX/bevacizumab) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The updated CRDF-004 data will first be presented during a rapid oral session at the 2026 American Society of Cli
4 - Cardiff Oncology, Inc. (0001213037) (Issuer)
3 - Cardiff Oncology, Inc. (0001213037) (Issuer)
3 - Cardiff Oncology, Inc. (0001213037) (Issuer)
- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC - - Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, with nine of the 14 patients remaining on treatment in these arms - - Onvansertib continues to be safe and well-tolerated with no overlapping or new toxicities when added to SoC - - Registrational trial planned in first-line RAS-mutated mCRC following successful End-of-Phase
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p<0.05) Data support selection of 30 mg onvansertib dose in combination with FOLFIRI/bev for planned registrational program; detailed data and registrational plans expected in the first half of 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today an
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naïve patients, as published in the Journal of Clinical Oncology – - Onvansertib continues to be safe and well-tolerated – - Company expects to provide final data and registrational plans in first half of 2026 – - Company to h
Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Operating Officer SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the appointment of Mani Mohindru, PhD, as President and Chief Executive Officer (CEO), following her time as Interim CEO, and that she will continue as a member of the Board. The Company also appointed Josh Muntner as Chief Financial Officer and Ajay Aggarwal, M
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res
First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)
SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)